List view / Grid view
In the first-ever efficacy trial of GSK’s Shingrix in China, no cases of shingles (herpes zoster) were reported after administration of the vaccine, new data shows.
A Phase I/II trial for the first mRNA-based shingles vaccine programme has been initiated by Pfizer Inc. and BioNTech SE.
Shingrix can effectively vaccinate adults over 50 years old against shingles for at least 10 years, new data shows.
New collaboration between Pfizer and BioNTech will develop an mRNA vaccine to combat shingles (herpes zoster virus).
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.